hypogonadism

Search with Google Search with Bing
Information
Disease name
hypogonadism
Disease ID
DOID:1924
Description
"A gonadal disease that is characterized by diminished functional activity of the gonads." [url:http\://en.wikipedia.org/wiki/Hypogonadism]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT02758431 Active, not recruiting N/A Cardiovascular Outcomes of Low Testosterone July 1, 2016 January 31, 2024
NCT00001412 Completed Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement December 1993 November 2001
NCT00004335 Completed Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle April 1993
NCT00004426 Completed N/A Leuprolide in Determining the Cause of Gonadotropin Deficiency August 1994 September 1998
NCT00004438 Completed N/A Leuprolide in Treating Adults With Hypogonadotropism September 1997 September 2002
NCT00048841 Completed Phase 3 Prevention of Osteoporosis in Men With Prostate Cancer May 2002 December 2005
NCT00080483 Completed Phase 2 Testosterone and Growth Hormone for Bone Loss in Men March 2004 September 2010
NCT00104572 Completed Phase 2 Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial. March 2004 January 2015
NCT00119483 Completed N/A Older Men and Testosterone September 2005 December 2007
NCT00136695 Completed Phase 2 Anastrozole Administration in Elderly Hypogonadal Men October 2004 October 2009
NCT00140998 Completed Phase 3 Estrogen Treatment (Oral vs. Patches) in Turner Syndrome January 2001 June 2004
NCT00141492 Completed Phase 2 Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes October 2004 June 2007
NCT00161421 Completed Phase 2 Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone March 2005 July 2006
NCT00161486 Completed Phase 1 The Effects of Testosterone on Prostate Tissue (ACYP-1) July 2004 November 2004
NCT00163566 Completed Phase 2 Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80 October 2004 September 25, 2006
NCT00170339 Completed Bone Density and Serum Testosterone in Male Methadone Maintained Patients April 2005 April 2007
NCT00179517 Completed Phase 2 Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo June 2001 April 2008
NCT00194675 Completed Phase 4 TRADE-Testosterone Replacement and Dutasteride Effectiveness March 2005 December 2010
NCT00202462 Completed N/A The Effect of Testosterone on Mood and Quality of Life November 2002 November 2006
NCT02697188 Completed Phase 2 Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men November 2007 April 2008
NCT01880086 Completed Phase 2 Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration August 2013 November 2017
NCT01887418 Completed Phase 1/Phase 2 Pharmacokinetic Study of Testosterone Enanthate September 2013 January 2014
NCT01893281 Completed Phase 4 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel July 2013 January 2014
NCT01919294 Completed Phase 2 Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS) July 2013 January 30, 2017
NCT02102646 Completed Phase 4 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism April 2014 October 2015
NCT02111434 Completed Phase 4 Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment July 2013 April 2014
NCT02111473 Completed Phase 4 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism May 2009 April 2014
NCT02159469 Completed Phase 3 Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism July 2014 November 2015
NCT02222558 Completed Phase 2 Oral Testosterone for the Treatment of Hypogonadism in Males September 2014 May 2015
NCT02233751 Completed Phase 1 Pharmacokinetic Study of Subcutaneous Testosterone Enanthate September 2014 October 2014
NCT02240966 Completed Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors August 2014 July 2016
NCT02248467 Completed Study of the Effect of Testosterone Treatment on Metabolic Parameters and Urinary Symptoms in Bariatric Patients May 2013 June 2018
NCT02366975 Completed Phase 4 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST November 2012 February 2017
NCT02433730 Completed Phase 4 Testosterone Therapy in Hypogonadal Men Treated With Opioids May 1, 2015 September 1, 2019
NCT02434562 Completed Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation April 2012 September 30, 2016
NCT02471157 Completed Hormonal Predictors of Oncologic Surgery January 2015 October 2016
NCT02504541 Completed Phase 3 Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism July 2015 June 2016
NCT02514629 Completed Phase 3 Testosterone, Metformin, or Both, for Hypogonadism in Obese Males July 4, 2013 July 12, 2016
NCT02665559 Completed Study of the Prevalence and Associated Factors With Hypogonadism in HIV + Men January 2013 March 31, 2018
NCT02670343 Completed Phase 1/Phase 2 Phlebotomy Study of Testosterone Undecanoate January 2016 March 2016
NCT02672592 Completed Phase 3 Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome January 2016 June 2017
NCT00001275 Completed Ovarian Follicle Function in Patients With Primary Ovarian Failure May 12, 1991 February 8, 2017
NCT02702882 Completed N/A The Efficacy Study of FUROSAP: A Testosterone Booster Supplement In Humans. February 2014 March 2017
NCT02722278 Completed Phase 3 A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men March 2016 November 2016
NCT02748005 Completed N/A Evaluation of Furosap in Human Volunteers August 2014 September 2015
NCT02777242 Completed Phase 2 Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism June 2016 August 2016
NCT02847806 Completed Phase 3 Effects of Replacement Therapy With Sexual Steroid Hormones on the Insulin Sensitivity of Hypogonadal Man January 2008 August 2016
NCT02921386 Completed Phase 2 The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate October 2016 January 21, 2017
NCT02937740 Completed Phase 4 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ October 2016 November 2017
NCT02956447 Completed Phase 2 Administration of Kisspeptin in Patients With Hyperprolactinemia November 17, 2017 July 29, 2023
NCT02959853 Completed Phase 4 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) June 2016 December 20, 2018
NCT03057899 Completed Phase 4 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS June 2015 December 2015
NCT03126656 Completed Phase 4 Effects of Testosterone on Myocardial Repolarization September 2016 April 2017
NCT03256292 Completed Long-term Lifestyle Change and Testosterone Replacement August 21, 2017 August 31, 2020
NCT03418896 Completed Phase 1 Extragonadal Effects of hCG on Calcium Homeostasis January 6, 2018 December 31, 2022
NCT03437109 Completed Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus December 6, 2017 February 1, 2019
NCT03484260 Completed Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone April 1, 2018 May 15, 2018
NCT03518034 Completed Phase 4 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men May 3, 2018 January 19, 2023
NCT03619330 Completed Phase 4 Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. December 2014 August 2015
NCT03792477 Completed Phase 1 A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males January 19, 2019 April 2, 2020
NCT04274894 Completed Phase 4 A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism May 12, 2020 January 7, 2022
NCT04320745 Completed Phase 4 A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants May 19, 2020 June 24, 2021
NCT04456296 Completed Phase 4 A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism June 30, 2020 July 12, 2023
NCT04492553 Completed Phase 2 Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality April 1, 2021 November 10, 2022
NCT04523480 Completed Phase 3 Testopel ® vs. Generic Testosterone Pellets. March 12, 2020 December 20, 2022
NCT04545450 Completed Phase 3 Effects of Testosterone Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolism in Transmen November 4, 2008 October 15, 2010
NCT04630275 Completed Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs December 1, 2020 April 24, 2023
NCT04673682 Completed Phase 1 A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845 November 16, 2020 June 7, 2022
NCT05752591 Completed Hypothalamic-pituitary Dysfunction in Diabetes May 25, 2018 March 14, 2024
NCT00220298 Completed Phase 3 Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism February 2003 October 2007
NCT00223860 Completed N/A Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury. July 2001 December 2007
NCT00244023 Completed Phase 3 Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone October 2005 July 2007
NCT00266864 Completed Phase 2/Phase 3 Testosterone Replacement Therapy in Chronic Spinal Cord Injury August 2003 December 2012
NCT00287586 Completed Phase 4 Testosterone Replacement in Older Men and Atherosclerosis Progression September 2004 May 12, 2012
NCT00290134 Completed Phase 2 A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism February 2006 October 2007
NCT00345969 Completed Phase 3 Exercise and Testosterone Therapy in Elderly Men With Physical Frailty November 2004 August 2009
NCT00349362 Completed Phase 4 Testosterone for Men With Insulin Treated Type 2 Diabetes July 2006 October 2008
NCT00351819 Completed Phase 2 Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception April 2006 November 2012
NCT00365794 Completed Phase 2 Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men August 2006 December 2014
NCT00372008 Completed Phase 2 Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males October 2006 April 2007
NCT00392457 Completed N/A Investigating the Regulation of Reproductive Hormones in Adult Men July 1995 February 2007
NCT00392912 Completed N/A Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone April 2007 July 2010
NCT00398580 Completed Phase 2 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men October 2006 October 2007
NCT00400335 Completed Phase 1 Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride October 2006
NCT00410306 Completed Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice October 2006 July 2010
NCT00415571 Completed Phase 2 Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors December 2006 August 2008
NCT00421460 Completed Phase 4 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction January 2007 May 2011
NCT00425568 Completed Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR December 2005
NCT00431197 Completed Phase 1 Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men February 2004 December 2007
NCT00433199 Completed Phase 3 Testosterone Treatment for Hypogonadal Men February 2007 April 2008
NCT00434824 Completed Phase 2 Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203) November 2001 July 2004
NCT00448955 Completed Phase 3 Open-Label Study of ARD-0403 in Testosterone Deficient Men May 2007 February 2008
NCT00452322 Completed Phase 2 Safety of Testosterone Undecanoate i.m. in Hypogonadal Men April 1997 January 2007
NCT00467870 Completed Phase 3 Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men March 2006 July 2009
NCT00470990 Completed N/A Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men October 2002 June 2008
NCT00472940 Completed Prevalence of Hypogonadism in Male Cancer Patients November 2006 September 2, 2020
NCT00483418 Completed Survey of Testosterone Levels in Male Cancer Patients June 2007 December 2009
NCT00487734 Completed Phase 4 Effect of Testosterone Replacement on Insulin Resistance August 2007 October 2010
NCT00504712 Completed Phase 4 Testosterone for Peripheral Vascular Disease February 2006 December 2009
NCT00522431 Completed Phase 3 A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone August 2007 March 2008
NCT00597051 Completed Phase 2 Study of 3 Doses of ARD-0403 in Testosterone Deficient Men October 2005 February 2006
NCT00613288 Completed N/A Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism September 2007 September 2009
NCT00613782 Completed Phase 2/Phase 3 Reandron in Diabetic Men Witn Low Testosterone Level January 2009 April 2014
NCT00624624 Completed Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism September 2009 March 2011
NCT00647868 Completed Phase 1 NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers May 2008 March 2009
NCT00663793 Completed Phase 1 ORAL T-6: Oral Androgens in Man-6 October 2008 June 2009
NCT00695110 Completed Phase 2 Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men June 2008 August 2009
NCT00702650 Completed Phase 3 A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations June 2008 July 2009
NCT00752869 Completed Phase 4 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement September 2008 March 2012
NCT00837616 Completed Phase 4 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism January 2009 December 2012
NCT00838838 Completed Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis September 2005 May 2009
NCT00847314 Completed Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients June 2007 October 2008
NCT00857168 Completed Phase 1 To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion January 2009 April 2009
NCT00857454 Completed Phase 3 A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations October 2008 August 2009
NCT00857961 Completed Phase 2 A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations October 2007 January 2008
NCT00957528 Completed Phase 1 Cycled Testosterone Replacement Study January 2006 December 2008
NCT00975650 Completed Phase 2 Efficacy and Tolerability of an Intra-Nasal Testosterone Product August 2009 May 2010
NCT00998933 Completed Phase 1 Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure October 2009 October 2009
NCT01061970 Completed Phase 2 Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy January 2007 October 2007
NCT01084265 Completed Phase 3 A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism February 2004 December 2005
NCT01104246 Completed Phase 1 Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men April 2010 September 2010
NCT01107067 Completed Phase 4 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism June 2008 December 2009
NCT01123278 Completed Phase 4 Testosterone Replacement in Metabolic Syndrome and Inflammation January 2004 October 2014
NCT01127659 Completed Phase 4 Testosterone Replacement in Men With Diabetes and Obesity May 2010 November 2015
NCT01133548 Completed Phase 1 Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males May 2010 July 2010
NCT01143818 Completed ESPRIT Study in Hypogonadal Men December 2007 August 2010
NCT01148433 Completed Quality of Life With TESTIM® May 2010 July 2011
NCT01160341 Completed Phase 4 Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism August 2009 January 2010
NCT01172366 Completed A Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application August 2010 September 2010
NCT01252745 Completed Phase 2 Efficacy of an Intranasal Testosterone Product August 2010 December 2010
NCT01323140 Completed Phase 2 Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems April 2011 July 2011
NCT01378299 Completed Phase 1 CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy October 1, 2011 November 7, 2017
NCT01386567 Completed Phase 2 A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203 July 2011 January 2013
NCT01419236 Completed Phase 2 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels August 2011 December 2013
NCT01560546 Completed Phase 4 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) March 2012 November 2013
NCT01709331 Completed Phase 3 A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937) February 11, 2013 April 8, 2015
NCT01717768 Completed Phase 2 Oral Testosterone for the Treatment of Hypogonadism October 2012 December 2014
NCT01748370 Completed Phase 4 Vitamin D Treatment and Hypogonadism in Men December 1, 2012 November 12, 2017
NCT01816295 Completed Phase 3 A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy May 2013 April 2015
NCT06455969 Not yet recruiting Phase 4 Adaptions and Resiliency to Multi-Stressor OpeRations June 17, 2024 August 1, 2026
NCT01511588 Recruiting Hormonal Regulation of Puberty and Fertility April 25, 2012
NCT04460872 Recruiting Phase 2 Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury January 31, 2021 June 30, 2025
NCT06247267 Recruiting The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population March 1, 2019 January 2025
NCT06191575 Recruiting 7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen Replacement Therapy November 29, 2022 October 29, 2026
NCT02953834 Recruiting Phase 1 Kisspeptin Influence on Glucose Homeostasis July 18, 2017 August 2024
NCT03887936 Recruiting Phase 4 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism October 1, 2019 September 30, 2025
NCT04833426 Recruiting Phase 3 Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy December 12, 2022 December 2027
NCT04731376 Recruiting Phase 1 Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone January 25, 2021 October 30, 2025
NCT04976595 Recruiting Phase 4 A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel July 1, 2021 December 2022
NCT06385509 Recruiting Phase 4 A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months May 10, 2024 February 2026
NCT06280807 Recruiting Observation of Environment and Reproductive-Endocrine Effects June 23, 2024 March 31, 2039
NCT01500447 Recruiting Inherited Reproductive Disorders April 25, 2012
NCT02356172 Terminated Psychological Outcomes in Isolated GnRH Deficiency February 4, 2015 July 16, 2019
NCT00240981 Terminated Phase 4 TOM: Testosterone in Older Men With Sarcopenia January 2005 December 2009
NCT00254553 Terminated Phase 2 A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815) July 2005 January 2007
NCT00743327 Terminated Androgen Deprivation Therapy Study October 2008 August 2012
NCT00848497 Terminated Early Phase 1 Testosterone for Penile Rehabilitation After Radical Prostatectomy November 2007 March 2013
NCT05205837 Terminated Phase 4 A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial November 24, 2021 August 15, 2023
NCT03335254 Terminated Phase 1/Phase 2 A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males November 6, 2017 May 3, 2018
NCT03345797 Terminated Phase 1 Evaluation of Testosterone Nasal Gel in Hypogonadal Boys March 1, 2018 April 11, 2022
NCT01084369 Terminated Phase 4 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism October 11, 2013 September 14, 2014
NCT01092858 Terminated Phase 4 NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH) September 2010 July 2011
NCT02712944 Terminated Phase 1 Testosterone Replacement in Renal Failure July 2016 March 2018
NCT00064987 Terminated Phase 2 Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism April 2001 October 2012
NCT02248701 Terminated Phase 2 Testosterone Plus Finasteride Treatment After Spinal Cord Injury April 27, 2017 August 13, 2021
NCT00504218 Terminated Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients July 17, 2007 June 12, 2018
NCT00529230 Terminated Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes December 11, 2001 February 19, 2004
NCT00562731 Terminated Phase 3 Open-Label Study of ARD-0403 in Testosterone Deficient Men October 2007 June 2008
NCT02419105 Terminated Phase 3 Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors September 2015 June 2020
NCT01460654 Terminated Phase 2 Testosterone and Alendronate in Hypogonadal Men October 2011 December 2014
NCT00696748 Unknown status Phase 3 The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men October 2005 December 2010
NCT01786473 Unknown status Phase 3 Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism December 2012
NCT00700024 Unknown status Phase 4 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men April 2008 February 2010
NCT02824809 Unknown status Association Between Testosterone Levels and COPD Severity June 2016 March 2017
NCT00204269 Unknown status Phase 3 Three-Year Trial on a New Testosterone Gel January 2003 September 2006
NCT01758029 Unknown status Testosterone Undecanoate and Quality of Life of Men and Spouses January 2013 July 2014
NCT03281187 Unknown status Phase 3 Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men. July 16, 2018 January 13, 2020
NCT00398034 Withdrawn Phase 2 Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study. October 30, 2006 September 6, 2007
NCT00440440 Withdrawn Phase 4 Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes August 2009 July 2012
NCT02137265 Withdrawn N/A Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism September 2015 October 2020
NCT00304213 Withdrawn Phase 4 Does Testosterone Improve Function in Hypogonadal Older Men March 2006 April 2009
NCT01689896 Withdrawn Phase 4 Testosterone and Pain Sensitivity August 2012 March 2015
NCT00710827 Withdrawn Phase 4 Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks October 2008 October 2008
NCT01377103 Withdrawn N/A Testosterone Therapy in Heart Failure July 2011 December 2012
NCT00705796 Withdrawn Phase 1 Influence of Administration Route of Testosterone on Male Fertility
NCT02082197 Withdrawn Phase 3 An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men March 2014 June 2015
NCT02803073 Withdrawn Phase 2/Phase 3 Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction August 2016 May 2017
NCT01940718 Withdrawn Early Phase 1 Androgen Regulation of Priapism in Sickle Cell Disease March 2014 January 2016
Disase is a (Disease Ontology)
DOID:2277
Cross Reference ID (Disease Ontology)
MESH:D007006
Cross Reference ID (Disease Ontology)
MIM:241100
Cross Reference ID (Disease Ontology)
MIM:312300
Cross Reference ID (Disease Ontology)
NCI:C9227
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:48130008
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0020619
HPO Human Phenotype ID (Human Phenotype Ontology)
HP:0000135
MeSH unique ID (MeSH (Medical Subject Headings))
D007006